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ABSTRACT 
Objectives: To assess the associations between microbiological markers of vaginal dysbiosis and 1) 
incident/cleared/type-swap/persistent high-risk human papillomavirus (hrHPV) infection; and 2) 
incident/cured/cleared/persistent high-grade cervical intraepithelial neoplasia (CIN2+) while 
controlling for persistent hrHPV infection.  
Design: Two nested case-control studies (N=304 and 236) within a prospective cohort of HIV-
positive women in Johannesburg, South Africa.  
Methods: Participants were examined for hrHPV type (InnoLipA), cervical dysplasia (histology), and 
vaginal microbiota (VMB) composition (V3-V4 Illumina HiSeq 2x300bp) at baseline and endline, a 
median of 16 months later.  
Results: Women with incident hrHPV compared to those who remained hrHPV-negative were less 
likely to have an optimal Lactobacillus crispatus/jensenii-dominated VMB type at endline (relative 
risk ratio (RRR)=0.125, p=0.019) but not at baseline. Having different hrHPV types at both visits was 
associated with multiple anaerobic dysbiosis markers at baseline (e.g. increased BV-anaerobes 
relative abundance: RRR=3.246, p=0.026). Compared to women without CIN2+ but with hrHPV at 
both visits, women with incident CIN2+ had increased Simpson diversity (RRR=7.352, p=0.028) and 
non-significant trends in other anaerobic dysbiosis markers at endline but not baseline. These 
associations persisted after controlling for age, hormonal contraception, and CD4+ count. Current 
hormonal contraceptive use (predominantly progestin-only injectables) was associated with increased 
CIN2+ risk over-and-above persistent hrHPV infection and independent of VMB composition. 
Conclusions: hrHPV infection (and/or increased sexual risk-taking) may cause anaerobic vaginal 
dysbiosis, but a bidirectional relationship is also possible. In this population, dysbiosis did not 
increase CIN2+ risk, but CIN2+ increased dysbiosis risk. The CIN2+ risk associated with progestin-
only injectable use requires further evaluation.  
Keywords: HPV, cervical intraepithelial neoplasia (CIN), cervical cancer, vaginal microbiota, 
lactobacilli, vaginal dysbiosis, 16S rRNA gene sequencing, women, HIV, South Africa. 
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INTRODUCTION 
Cervical cancer is the fourth most common cancer affecting women worldwide [1]. Persistent 
genital infection with high-risk human papillomavirus (hrHPV) types is a necessary trigger, 
but hrHPV infection and high-grade cervical intraepithelial neoplasia (CIN) lesions may 
regress without treatment [2]. Cervical cancer and hrHPV prevalences are particularly high in 
sub-Saharan Africa, including South Africa, which currently also has the highest HIV 
prevalence worldwide [3]. Women living with HIV have a higher prevalence of genital 
hrHPV infection than the general population [4], and a higher risk of progression to CIN or 
cervical cancer, likely due to HIV-induced immunosuppression [5]. 
 
Persistent hrHPV infection does not always result in CIN/cancer, and other exposures are 
thought to play important roles. One of these is vaginal microbiota (VMB) dysbiosis. An 
optimal VMB is dominated by lactobacilli. The most common type of vaginal dysbiosis is 
bacterial vaginosis (BV), which is characterised by a persistent decrease in lactobacilli and 
increase in fastidious anaerobes (referred to as BV-anaerobes). BV affects 30-40% of women 
worldwide at any given time [6]. A recent systematic review and meta-analysis of 14 
longitudinal studies published between 2003 and 2017 showed that BV is associated with 
increased risks of incident hrHPV (relative risk 1.33), hrHPV persistence (1.18), and 
CIN/cancer (2.01) [7]. However, most of these studies (11/14) used crude VMB assessments 
by microscopic methods only. Furthermore, in all studies, women with high-grade 
CIN/cancer were compared with those without, regardless of their hrHPV status. The review 
could therefore not disentangle the impact of VMB characteristics on hrHPV infection from 
progression to CIN/cancer during or after persistent hrHPV infection.  
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We addressed the shortcomings of these earlier studies by conducting two nested case-control 
studies within the ‘HPV in Africa Research Partnership’ (HARP) study in South African 
women living with HIV [8,9]: the hrHPV sub-study and the CIN sub-study. We used 
appropriate control groups in each sub-study and incorporated molecular VMB assessments. 
 
METHODS 
The HARP study aim was to improve cervical cancer prevention programs for HIV–infected 
African women and procedures have been described elsewhere [8,9]. HIV-infected women 
(N=623), aged 25-50, were recruited from HIV treatment centres and surrounding 
communities in Johannesburg in 2011 and 2012. Exclusion criteria were previous treatment 
for cervical cancer, previous hysterectomy, and being pregnant or less than eight weeks 
postpartum. Enrolment was stratified by antiretroviral therapy status (on therapy versus 
therapy-naïve, following the 2010 World Health Organisation guidelines that used a CD4+ 
350 cells/μl cut-off [10]) in a 2:1 ratio. Women were followed up every six months for a 
median of 16 months (range 11-22 months), but only baseline and endline data were used for 
the VMB sub-studies. The hrHPV sub-study (N=304) included women with CIN1 or lower 
(≤CIN1) at both visits who had never received cervical treatment, and categorised them into 
mutually exclusive categories as follows (Figure 1): twice hrHPV-negative (n=37; referred to 
as persistent hrHPV-negative controls), incident hrHPV (n=43; no hrHPV types at baseline 
but at least one at endline), cleared hrHPV (n=65; at least one hrHPV type at baseline and 
none at endline), hrHPV type-swap (n=67; different hrHPV types at the two visits), and 
persistent type-specific hrHPV (n=92). The CIN sub-study (N=236) included women with 
CIN2 or higher (CIN2+) on at least one visit, who did or did not receive cervical treatment in 
between the two visits, and categorised them into mutually exclusive categories as follows: 
incident CIN2+ (n=22), cured CIN2+ after treatment (n=50), spontaneous CIN2+ clearance 
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in the absence of treatment (n=14), persistent or recurrent CIN2+ (n=25; five women were 
treated but had CIN2+ recurrence and 20 women were not treated and had CIN2+ at both 
visits), and prevalent CIN2+ (n=33; data available for one visit only). In this sub-study, 
women with ≤CIN1 but persistent type-specific hrHPV at both visits were used as the control 
group (n=92; referred to as persistent hrHPV-positive controls). This group was included in 
both sub-studies, as a comparison group in the hrHPV sub-study and as a control group in the 
CIN sub-study, making the total sample size of women enrolled in the two sub-studies 448.   
 
Diagnostic laboratory assessments 
HIV-1 serostatus was diagnosed according to national guidelines [11]. CD4+ T-lymphocyte 
counts were determined by FACScount (Becton-Dickinson, Franklin Lakes, New Jersey, 
USA) and plasma HIV viral load by COBAS Taqman (Roche Diagnostics, Johannesburg, 
South Africa). All samples were assessed for hrHPV qualitatively by Digene HC-II or 
CareHPV test (both Qiagen, Gaithersburg, Maryland, USA) and by INNO-LiPA HPV 
Genotyping Extra (Fujirebio, Courtaboeuf, France), classifying 13 types as high-risk (16, 18, 
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68; Supplement 1: Methods, 
http://links.lww.com/QAD/B541) [12]. Cervical dysplasia status was assessed by 
Papanicolaou smear cytology, visual inspection with acetic acid or Lugol’s iodine, and 
colposcopy. If any of these or qualitative hrHPV testing were positive, histology of four-
quadrant cervical biopsies was done using the three-tier CIN classification system [13], and 
binarised as ≤CIN1 or CIN2+ based on the highest reading. All histological slides from 
women with CIN2+ and 5-10% of slides from women with ≤CIN1 were reviewed by the 
HARP Endpoint Committee of five pathologists for consensus classification [14]. BV was 
diagnosed by Gram stain Nugent scoring [15], and vaginal yeast infection by the presence of 
yeasts on Gram stain. Women were also screened for other sexually transmitted infections 
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(STIs; Supplement 1: Methods, http://links.lww.com/QAD/B541). hrHPV, cervical dysplasia, 
and CD4+ count assessments were done at both visits, and the other procedures at baseline 
only.  
 
Molecular VMB testing 
Vaginal swabs were stored at room temperature in Boonfix medium (a patented fixative 
containing ethanol, low molecular weight polyethylene glycol, and acetic acid). We first 
determined that this fixative was suitable for sequencing (Supplement 1: Methods, 
http://links.lww.com/QAD/B541). DNA was extracted from one swab per woman per visit 
(N=873), using lysozyme lysis combined with the Qiagen DNeasy Blood and Tissue kit 
(Qiagen, Manchester, UK) with inclusion of the swab head up to and including the proteinase 
K step. The 16S rRNA gene V3-V4 region was amplified and sequenced on an Illumina 
HiSeq 2500 instrument (Illumina, San Diego, CA, USA). 
 
Molecular data processing 
Molecular data processing steps are described in Supplement 1 (Methods, 
http://links.lww.com/QAD/B541). Briefly, Swarm v2.1.13 was used to assign reads to 
operational taxonomic units (OTUs) and taxonomic assignments were made using RDP 
classifier against the Silva v128 database (Supplement 1: Methods, 
http://links.lww.com/QAD/B541) [16]. Low read count (<100 reads), non-bacterial, and 
contaminant OTUs were removed. Relative abundances were rarefied at 1,039 reads using the 
GUniFrac v1.0 package in R v3.4.1 (R Foundation for Statistical Computing 2015, Vienna, 
Austria). The rarefied OTU relative abundance table consisted of 1981 OTUs in 871 samples, 
of which 246 were non-minority OTUs (relative abundance of at least 1% in at least one 
sample). 
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Data reduction for biostatistical modelling was done in three different ways. First, the 
Simpson diversity index (1-D) was calculated for each sample, ranging from zero (no 
diversity) to one (infinite diversity). Second, each OTU was assigned to one of four ‘bacterial 
groups’ based on the published literature (Supplement 2, http://links.lww.com/QAD/B541) as 
follows: 1) lactobacilli; 2) BV-anaerobes; 3) pathobionts (bacteria with higher intrinsic 
pathogenicity than BV-anaerobes that are not typically associated with BV; also includes STI 
pathogens); and 4) ‘other bacteria’ (skin and Bifidobacteria). The proportion of sequencing 
reads assigned to a specific OTU in a sample is called the relative abundance of that OTU. 
For each sample, relative abundances of OTUs belonging to the same bacterial group were 
summed (Supplement 1: Methods, http://links.lww.com/QAD/B541). This resulted in four 
relative abundances (one for each bacterial group) per sample, which sum to one. Third, we 
used hierarchical clustering based on Euclidean distance to pool samples into seven VMB 
types (Supplement 1: Figure S1, http://links.lww.com/QAD/B541). 1) Lactobacillus iners-
dominated (Li; >70% lactobacilli of which L. iners was the most common); 2) L. crispatus or 
L. jensenii-dominated (Lcj; also >70% lactobacilli of which L. crispatus or L. jensenii were 
the most common); 3) lactobacilli and anaerobes (LA; >10% lactobacilli with the remainder 
BV-anaerobes); 4) high diversity BV-anaerobes (BV), 5) BV-anaerobe-dominated (AD; 
>50% Gardnerella vaginalis or Atopobium vaginae); 6) pathobionts-characterized (PB; 
>25% pathobionts) and 7) Bifidobacterium-dominated (BD). An increased Nugent score, 
Simpson index, or BV-anaerobes relative abundance, a reduced lactobacilli relative 
abundance, and VMB types LA, BV, and AD were considered markers of (transition to/from) 
anaerobic vaginal dysbiosis. The pathobionts and ‘other bacteria’ bacterial groups, and PB 
and BD VMB types, represent poorly characterised VMB states and were uncommon.  
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Statistical analyses 
Statistical analyses were performed in R v3.4.1 and Stata v13 (StataCorp, College Station, 
TX, USA). Baseline characteristics between the parent study and sub-studies were compared 
by Kruskal Wallis test for continuous and Chi-squared or Fisher’s exact test for categorical 
variables. Unadjusted multinomial logistic regression models were carried out for three multi-
category outcome variables: the hrHPV and CIN outcomes as described above and in Figure 
1, and a combined hrHPV/CIN outcome (4 mutually exclusive groups; N=448) to optimise 
statistical power: ≤CIN1 and no hrHPV at both visits (n=37), ≤CIN1 at both visits and hrHPV 
at one visit (n=108), ≤CIN1 and hrHPV at both visits (n=159), and CIN2+ regardless of 
hrHPV status at one or both visits (n=144). Each unadjusted model included one outcome and 
one baseline or endline VMB variable but yielded multiple relative risk ratios (RRRs) due to 
the multi-category nature of the outcomes. For example, models with the combined outcome 
yielded three RRRs: case group 1 versus controls, case group 2 versus controls, and case 
group 3 versus controls. Multivariable models were carried out in the same manner but for 
the combined outcome only, and were adjusted for age, CD4+ count at baseline or endline, 
and hormonal contraceptive use at baseline or during the study. Potential confounders were 
selected a priori based on the published literature and the above-mentioned confounders were 
consistently associated with hrHPV/CIN outcomes and VMB variables in our data.  
 
Ethical statement 
All participants provided written informed consent. The study was conducted in accordance 
with the Helsinki Declaration, and approved by the research ethics committees of 
Witwatersrand University, London School for Hygiene and Tropical Medicine, and 
University of Liverpool. 
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RESULTS 
The 448 women selected for the sub-studies did not differ from those not selected (N=175), 
except that they were more likely to be on antiretroviral therapy (70.1% versus 52.6%) 
(Supplement 1: Table S1, http://links.lww.com/QAD/B541). The median age was 34 
(interquartile range 30-39) (Table 1). At baseline, the majority of women reported to have a 
regular male sex partner and one sex partner in the last three months. Vaginal cleansing was 
practiced at least weekly by 41.5% of women. A quarter (25.2%) reported current hormonal 
contraceptive use, which consisted predominantly of intramuscular injections of 
medroxyprogesterone acetate or norethindrone enanthate. The median CD4+ count was 423 
(interquartile range 317-566). STIs other than HIV and HPV were common, especially herpes 
simplex virus type 2 (95.3%) and Trichomonas vaginalis (15.6%), but vaginal yeast 
infections were less common (7.5%). None of these characteristics differed between the 
hrHPV and CIN comparison groups, except for injectable contraceptive use, which was 
significantly more common in the cured, cleared, and persistent CIN2+ groups (34.0, 57.1, 
and 36.0%) compared to the other groups (4.6-24.3%) (Supplement 1: Table S2, 
http://links.lww.com/QAD/B541). 
The majority of women had at least one hrHPV type at baseline (79.7%) and endline (70.8%), 
and 42.9% had BV by Nugent score at baseline. The mean Simpson index was 0.54, and the 
mean bacterial group relative abundances 0.48 for lactobacilli, 0.49 for BV-anaerobes, 0.03 
for pathobionts, and 0.01 for ‘other bacteria’, for all women combined at baseline (Table 1). 
The most common VMB types at baseline were Li (26.3% of women), LA (25.3%), and BV 
(33.8%) (Table 1). The Lcj (6.2%) and AD (6.6%) types were less common, and the PB and 
BD types were rare. As expected, the median Simpson index and mean bacterial group 
relative abundances differed per VMB type (Supplement 1: Figure S1, 
http://links.lww.com/QAD/B541). The overall proportions of women with each VMB type 
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were similar at endline, but only 143/414 (35%) of individual women with two VMB 
assessments had the same VMB type at both visits. Women with the Lcj or BV type at 
baseline were most likely to have the same VMB type at endline (50.7% and 44.4%, 
respectively) while those with Li (25.5%), LA (26.2%), or AD types (14.8%) were less 
stable. The median Bray-Curtis similarities between baseline and endline samples were: Lcj 
33%, Li 44%, LA 40%, BV 22%, BD 19%, and PB 6.7%.  
Stacked bar graphs of the proportions of women with each VMB type at baseline and endline 
by outcome group are shown in Figure 2, and data for all VMB characteristics by outcome 
group in Supplement 1 (Table S3, http://links.lww.com/QAD/B541). In the hrHPV sub-study, 
unadjusted multinomial logistic regression models showed that baseline VMB compositions 
of women who acquired or cleared hrHPV during the study did not significantly differ from 
the baseline VMB compositions of the persistent hrHPV-negative controls (Table 2). 
However, women who acquired hrHPV were much less likely to have an optimal Lcj VMB 
type at endline (RRR=0.125, p=0.019), and women who cleared hrHPV were more likely to 
have anaerobic dysbiosis markers at endline (reaching significance for Simpson diversity: 
RRR=3.856, p=0.034). Women in the type-swap group were more likely to have anaerobic 
dysbiosis markers at baseline (significantly increased Nugent score, Simpson diversity, and 
BV-anaerobes relative abundance, and significantly decreased Lactobacilli relative 
abundance), and women in the type-swap and type-specific persistence groups had non-
significant trends towards a lower likelihood of having an optimal Lcj VMB type at endline 
(Table 2).  
 
In the CIN sub-study, unadjusted multinomial logistic regression models showed that women 
who had CIN2+ at least once during the study were more likely to have anaerobic dysbiosis 
markers at baseline and endline than persistently hrHPV-negative controls (Table 2). 
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However, when compared to persistent hrHPV-positive controls, the endline – but not the 
baseline – VMB compositions of women with incident or persistent/recurrent CIN2+ were 
more dysbiotic. 
 
The impact of potential confounders on these associations was assessed in multinomial 
logistic regression models with the combined hrHPV/CIN outcome (Table 3). Women who 
had CIN2+ at least once during the study, compared to persistently hrHPV-positive controls, 
were younger (RRR=0.954; p=0.021), more likely to use hormonal contraception at baseline 
(RRR 2.358; p=0.001) and during the study (RRR=1.317; p=0.008), and had a higher log10 
HIV-1 plasma viral load (RRR=1.200, p=0.050). These same women compared to 
persistently hrHPV-negative controls were younger (RRR=0.881; p<0.001) and had a trend 
towards lower CD4+ count (RRR=0.998, p=0.053).  Smoking, sexual behaviour, vaginal 
cleansing, bacterial/protozoal STIs, and yeasts on vaginal Gram stain were not significantly 
associated with any of the outcomes. The associations between the combined hrHPV/CIN 
outcome and individual VMB composition variables one at a time were similar to those in 
Table 2 for the more detailed separate hrHPV and CIN outcomes: hrHPV at one visit 
compared to persistent hrHPV-negative controls was associated with none of the VMB 
variables, hrHPV at both visits compared to persistent hrHPV-negative controls was 
associated with baseline anaerobic dysbiosis, and CIN2+ at least once compared to persistent 
hrHPV-positive controls was associated with endline anaerobic dysbiosis (Table 3). In 
addition, CIN2+ at least once compared to persistent hrHPV-negative controls was associated 
with anaerobic dysbiosis at baseline and endline. All multivariable models were controlled 
for age, hormonal contraceptive use, and CD4+ count at baseline or endline, but this did not 
change the results (Table 3).  
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DISCUSSION 
Our results support the associations between vaginal dysbiosis, hrHPV, and high-grade CIN 
that have been reported previously [7] and are most consistent with changes in hrHPV 
infection and CIN status preceding changes in VMB composition. However, we compared 
data from two visits only, about 16 months apart, and bidirectional relationships can therefore 
not be ruled out. Women who did not have any hrHPV at baseline and acquired hrHPV 
during follow-up were similar to persistent hrHPV-negative controls at baseline but not at 
endline, suggesting that hrHPV acquisition altered the VMB rather than vice-versa. Women 
with hrHPV type-swap were more dysbiotic at baseline than women with persistent type-
specific hrHPV infection, suggesting that frequency of hrHPV acquisition may determine the 
likelihood of anaerobic dysbiosis to a larger extent than type-specific hrHPV persistence. 
However, women who have increased exposure to hrHPV types most likely also have 
exposure to a higher number of male sex partners and/or sex acts, which in themselves are 
risk factors for vaginal dysbiosis [17]. We assessed multiple sexual behaviour characteristics 
for potential confounding but residual confounding may have been present. 
 
Women with incident CIN2+ were more likely to have anaerobic dysbiosis at endline, but not 
baseline, when compared to women with hrHPV infection but no CIN2+ at both visits. 
Anaerobic dysbiosis risk therefore seems to increase concurrently with CIN2+ development, 
suggesting that VMB composition does not play a role in CIN2+ development over-and-
above the presence of a persistent hrHPV infection. CIN2+ at least once compared to 
persistent hrHPV-negative controls was associated with anaerobic dysbiosis at baseline and 
endline, which is similar to findings from previous studies to date that compared women with 
and without CIN2+ regardless of hrHPV status [7]. hrHPV status should therefore be taken 
into account when evaluating the VMB-CIN relationship, as we had hypothesised. 
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An additional important finding was that hormonal contraceptive use (which consisted 
predominantly of intramuscular injections of medroxyprogesterone acetate or norethindrone 
enanthate) increased CIN2+ risk over-and-above persistent hrHPV infection. Hormonal 
contraception is known to decrease anaerobic dysbiosis risk [18], and current use was 
associated with decreased likelihood of anaerobic dysbiosis in this study (data not shown). 
The association with CIN2+ risk is therefore unlikely to be mediated by VMB composition. 
In the overall South African HARP cohort of 623 women, CIN2+ prevalence at baseline was 
higher among current injectable users compared to never or past users of any hormonal 
contraception (odds ratio 2.75, adjusted for condom use, antiretroviral therapy status, and 
CD4+ count) [19]. No association was observed for CIN2+ prevalence and combined oral 
contraceptive use. The potential roles of different progestin-only injectable contraceptives on 
CIN2+ development by hrHPV and HIV status should be evaluated urgently.  
 
Only three other studies have assessed associations between molecular VMB assessments and 
hrHPV outcomes longitudinally, and none for CIN outcomes. Brotman et al reported that 
lactobacilli-dominance, and particularly L. gasseri-dominance, was associated with decreased 
HPV incidence and increased HPV remission rates in 32 HIV-negative women [20]. Reimers 
et al (N=68) found that high L. crispatus relative abundance reduced HPV detection during 
follow-up (after controlling for HIV-status), but found no associations with lactobacilli as a 
group or for other individual Lactobacillus species [21]. Di Paola et al compared baseline 
samples from 27 women who had cleared their HPV infection one year later with 28 women 
with persistent infection (all HIV-negative), and found a difference in anaerobic dysbiosis 
prevalence (7.4% and 43.0%, respectively) [22]. None of these studies contradict our 
findings, but they do suggest that a bidirectional relationship between VMB and HPV status 
is likely.  
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HPV causes alterations in cell physiology as well as innate immune response suppression of 
infected cervicovaginal mucosal cells [23]. Neoplastic cells have a drastically increased 
glucose demand compared to healthy cells, and ferment glucose into lactate instead of carbon 
dioxide. These altered mucosal environments likely facilitate BV-anaerobe growth at the 
expense of Lactobacillus growth which causes cervicovaginal dysbiosis [24]. However, 
cervicovaginal dysbiotic states (which could be caused by multiple factors in addition to HPV 
infection or neoplastic cells) reduce cervicovaginal barrier function [25] and alter metabolic 
profiles [24], and these may in turn facilitate HPV acquisition and CIN/cancer development, 
respectively.  
 
Strengths of our study included a much larger sample size than similar previous studies, high 
quality longitudinal hrHPV, CIN, and VMB assessments, and adjustments for several known 
confounders. However, an even larger sample size and more frequent follow-up assessments 
would have been preferable. The study lacked quantitative HPV and VMB data at both time 
points, and HIV viral load at endline, and a full assessment of the HPV virome would have 
added value [26]. Some associations may have been detected due to chance because of the 
high dimensionality of our data and multiple testing. Finally, our results may not be 
generalisable to HIV-negative women, HIV-positive women on ART with sustained 
undetectable virus, and women in other world regions. 
 
In conclusion, hrHPV exposure (and/or increased sexual risk-taking) may cause vaginal 
dysbiosis, but a bidirectional relationship is possible. At-risk women may therefore benefit 
from interventions that promote vaginal lactobacilli. In our population, vaginal dysbiosis does 
not increase CIN2+ risk, but CIN2+ increases vaginal dysbiosis risk, when hrHPV status is 
taken into account. Interventions that promote vaginal lactobacilli may therefore not prevent 
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CIN2+ development after a persistent hrHPV infection has taken hold. The potential 
association between progestin-only injectable contraceptive use and CIN2+ development 
deserves urgent attention.  
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Enrolled in VMB sub-studies (N=448) 
VMB-hrHPV sub-study (N=304) n VMB-CIN sub-study (N=144) n ≤CIN1 at both visits AND: Regardless of hrHPV status 
Control group: No hrHPV at both visits 37 Control group: ≤CIN1 but same hrHPV at both visits2 92 
Incident hrHPV 43 Incident CIN2+ 22 
Cleared hrHPV 65 Cured CIN2+ (after treatment) 50 
Type swap 67 Cleared CIN2+ (spontaneously) 14 
≤CIN1 but same hrHPV at both visits2 92 Persistent CIN2+ 25 
  [Prevalent CIN2+]3 33 
 
Abbreviations: CIN cervical intraepithelial neoplasia, hrHPV high-risk human papillomavirus, VMB vaginal 
microbiota. N and n refer to the number of women.  
1. One woman had had cervical cancer treatment prior to enrolment and was erroneously enrolled into the HARP study 
(N=623 correctly enrolled women). In addition, six women were treated for CIN2+ at baseline based on local histology 
results but their baseline histology was subsequently downgraded to ≤CIN1 by the HARP Endpoint Committee. This 
became clear after the samples had already been sequenced. Data from these seven women were included in the 
bioinformatics pipeline but excluded from all epidemiological analyses.  
2. These are the same 92 women. In this figure, they are included in the sample size of the VMB-hrHPV sub-study but not 
the sample size of the VMB-CIN sub-study. The total sample size of the VMB-CIN sub-study is therefore 144+92=236. 
3. We required two full assessments per person except for women with CIN2+ at one visit and a missing histology result at 
the other visit. These are referred to as prevalent CIN2+ cases (n=29 at the baseline visit, and n=4 at the endline visit). 
They were included in some but not all analyses. Of the 59 women with missing endline data, 21 were lost to follow up, 
16 moved away, ten were withdrawn by the clinician (including referral for suspected cervical carcinoma or 
hysterectomy), seven withdrew due to personal circumstances and/or being unwilling to undergo further testing and five 
died (two from HIV-related causes and three from other causes). The other women had incomplete HPV and/or CIN 
results. 
HARP enrolled (N=624)1





Selected for VMB-hrHPV sub-
study (n=304)
Treated for CIN2+ prior to 
enrollment (n=1)1 or at baseline 
(n=6)1





Selected for VMB-CIN 
sub-study (n=144)
HPV, histology, clinical data not 
complete for both visits (n=115)
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Abbreviations: AD BV-anaerobe-dominated, B baseline visit, BD Bifidobacterium-
dominated, BV bacterial vaginosis-like, CIN cervical intraepithelial neoplasia, E endline visit, 
hrHPV high risk human papillomavirus, LA lactobacilli and BV-anaerobes, Lcj Lactobacillus 
crispatus or L. jensenii-dominated, Li L. iners-dominated, PB pathobionts-characterised, 
VMB vaginal microbiota. 
The number of women is equal at the baseline and the endline visit in all outcome groups (see 
Figure 1 for sample sizes), with the exception of the prevalent CIN2+ groep: 29 women were 
seen at baseline only and four women were seen at endline only.  
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Table 1. Participant characteristics at baseline and endline (all groups combined)  




Age (median, IQR) 34 (30-39) NA 
Current smoker (n %) 24 (5.4) 26 (6.0) 






Number of male sex partners last 3 (baseline) or 6 (endline) 





77 (17.2)  
345 (77.0)  





Ever used hormonal contraception (n %) 386 (86.2) 369 (82.4) 
Current use of hormonal contraception (n %)1 
− Combined pill (n %) 
− Combined patch (n %) 
























Practices vaginal cleansing at least weekly (n %) 186 (41.5) NA 
Clinical and laboratory results   
Antiretroviral therapy: 
− On therapy at baseline and endline 
− Started therapy during the study 









CD4+ count in cells/μl (median, IQR)2 423 (317-566) 
426 (324-
565) 
HIV undetectable in plasma (n %)3 103 (23.4) NA 
HIV plasma viral load log10 copies/ml (median, IQR)3 2.6 (1.6-3.9) NA 
Any high-risk human papillomavirus by genotyping 357 (79.7) 306 (70.8) 
Yeasts on vaginal Gram stain (n %) 33 (7.5) NA 
Trichomonas vaginalis by NAAT (n %) 70 (15.6) NA 
Chlamydia trachomatis by NAAT (n %) 24 (5.4) NA 
Neisseria gonorrhoeae by NAAT (n %) 10 (2.2) NA 
Mycoplasma genitalium by NAAT (n %) 36 (8.0) NA 
Active syphilis by serology (n %) 3 (0.7) NA 
Herpes simplex virus type 2 by serology (n %) 425 (95.3) NA 
VMB characteristics   
Bacterial vaginosis by Nugent 7-10 (n %) 188 (42.9) NA 








BV-anaerobes relative abundance (mean, 95% CI)4 0.49 (0.45- 0.50 (0.46-
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0.52) 0.54) 




Other bacteria relative abundance (mean, 95% CI)4 0.01 (0.01-
0.01) 
0.01 (0-0.02) 
Vaginal microbiota type (n %):4 
- Lactobacillus crispatus/L. jensenii-dominated (Lcj) 
- L. iners-dominated (Li) 
- Bifidobacterium-dominated (BD) 
- Lactobacilli + BV-anaerobes (LA) 
- BV-like (BV) 
- BV-anaerobe-dominated (AD) 
- Pathobiont-characterised (PB) 



















Abbreviations: BV bacterial vaginosis, CI confidence interval, IQR inter-quartile range, NA not 
assessed, NAAT nucleic acid amplification test. 
1.N=420 at endline.  
2.N=381 at endline. 
3.N=439 at baseline. If below the detection limit of 40 copies/ml, log10 of 40 was used. 
4.N=438 at baseline and N=417 at endline. 
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Table 2: Bivariable multinomial logistic regression models with hrHPV and CIN outcomes 
hrHPV outcome categories All 
≤ CIN1; control group: no hrHPV at 
both visits 
Baseline VMB RRR p Endline VMB RRR p 
Incident hrHPV Lcj vs Li 
 
0.196 0.171 Lcj vs Li 





       
Cleared hrHPV None 
 
 Simpson 











       
hrHPV type-swap Nugent 
Simpson 
AD vs Li 















Lcj vs Li 0.397 0.174 
       
Type-specific hrHPV persistence BV-anaerobes RA 1.936 0.188 Simpson 





       





       


















CIN outcome categories 
Control group: ≤CIN1 and hrHPV-
positive at both visits 
Baseline VMB RRR p Endline VMB RRR p 
Incident CIN2+ None   Simpson 
LA vs Li 
BV vs Li 















       
Cured CIN2+ Lcj vs Li 2.836 0.139 LA vs Li 2.187 0.144 
       
Cleared CIN2+ AD vs Li 8.662 0.021 Simpson 





       
Persistent CIN2+ None   Simpson 








       
CIN2+ at one or two visits Nugent 1.087 0.170 Simpson 5.981 0.003
Control group: no hrHPV at 
both visits 










LA vs Li 
BV vs Li 














Abbreviations: BV bacterial vaginosis-like, CIN cervical intraepithelial neoplasia, hrHPV high-risk 
human papillomavirus, LA lactobacilli and BV-anaerobes, Lcj Lactobacillus crispatus or L. jensenii-
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dominated, Li L. iners-dominated, RA relative abundance, RRR relative risk ratio, VMB vaginal 
microbiota. Each model includes one multi-category outcome and one VMB independent variable. 
The VMB independent variable in each hrHPV outcome category is compared to that in the 
persistent hrHPV-negative control group. VMB variables tested: Nugent score (baseline only), 
Simpson diversity index, VMB type, and relative abundance of lactobacilli, BV-anaerobes, 
pathobionts, and other bacteria. Only results with p<0.2 are shown in the table: see Table S4 in 
Supplement 1 , http://links.lww.com/QAD/B541 for full results including 95% confidence intervals. 
‘None’ means that none of the VMB variables were associated with the outcome listed in the first 
column at p<0.2. Statistically significant results (p<0.05) are shown in bold.  
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Table 3. Multinomial logistic regression models with combined hrHPV/CIN outcome 
Bivariable models1 
Combined hrHPV/CIN outcome2 
All ≤CIN1; hrHPV at 
one visit vs no 
hrHPV at both visits 
All ≤CIN1; hrHPV at 
both visits vs no 
hrHPV at both visits 
CIN2+ at one or both 
visits vs ≤CIN1 and 
no hrHPV both visits 
CIN2+ at one or both 
visits vs ≤CIN1 and 
hrHPV at both visits 
RRR p RRR p RRR p RRR p 
Age (per year) 0.945 0.077 0.923 0.010 0.881 <0.001 0.954 0.021 
Current smoker at baseline 1.385 0.774 2.939 0.308 1.839 0.574 0.626 0.339 
Regular partner at baseline3 1.178 0.516 1.547 0.073 1.509 0.094 0.975 0.872 
# sex partners 3 months prior 
to baseline4 1.877 0.113 1.773 0.131 1.919 0.090 1.082 0.752 
On hormonal contraception at 
baseline 0.691 0.401 0.628 0.270 1.481 0.337 2.358 0.001 
Any hormonal contraception 
during study5 1.074 0.671 0.923 0.627 1.216 0.229 1.317 0.008 
Current condom use6 0.979 0.931 0.945 0.809 0.763 0.249 0.807 0.140 
Vaginal cleansing at least 
weekly 
0.997 0.987 0.820 0.295 0.878 0.493 1.070 0.580 
On ART at baseline 1.877 0.138 1.179 0.674 0.800 0.568 0.678 0.114 
CD4 count (per cell/μl) 1.000 0.946 0.999 0.348 0.998 0.053 0.999 0.128 
Log10 HIV plasma viral load 0.830 0.257 1.026 0.869 1.231 0.175 1.200 0.050 
CT, NG or syphilis7 3.673 0.223 1.658 0.641 3.876 0.198 2.338 0.076 
Nugent score baseline8 1.049 0.444 1.126 0.050 1.087 0.170 0.965 0.367 
Yeasts on Gram stain 
baseline8 
2.059 0.511 3.525 0.231 3.256 0.265 0.924 0.847 
Simpson index baseline 1.460 0.518 2.066 0.198 1.717 0.344 0.831 0.619 
Simpson index endline 2.395 0.132 2.165 0.162 5.981 0.003 2.763 0.012 
Lactobacilli RA baseline 0.593 0.276 0.412 0.055 0.433 0.075 1.051 0.865 
Lactobacilli RA endline 0.589 0.252 0.651 0.333 0.352 0.025 0.541 0.043 
BV-anaerobes RA baseline 1.725 0.266 2.386 0.065 2.561 0.049 1.073 0.809 
BV-anaerobes RA endline 1.453 0.426 1.287 0.575 2.412 0.060 1.874 0.039 
Pathobionts RA baseline 0.594 0.764 1.391 0.832 0.375 0.576 0.269 0.275 
Pathobionts RA endline 452.02 0.275 524.55 0.262 376.63 0.289 0.718 0.744 
Multivariable models9 
All ≤CIN1; hrHPV at 
one visit vs no hrHPV 
at both visits 
All ≤CIN1; hrHPV at 
both visits vs no 
hrHPV at both visits 
CIN2+ at one or both 
visits vs ≤CIN1 and 
no hrHPV both visits 
CIN2+ at one or both 
visits vs ≤CIN1 and 
hrHPV at both visits 
aRRR p aRRR p aRRR p aRRR p 
Nugent score baseline8 1.042 0.518 1.114 0.081 1.073 0.262 0.963 0.348 
Simpson baseline 1.381  0.585 1.941 0.246 1.653 0.391 0.852 0.671 
Simpson endline 2.476 0.143 2.094 0.217 7.691 0.002 3.673 0.004 
Lactobacilli RA baseline 0.587 0.267 0.404 0.051 0.417 0.067 1.034 0.911 
Lactobacilli RA endline 0.534 0.207 0.631 0.339 0.325 0.027 0.515 0.050 
BV-anaerobes RA baseline 1.729 0.264 2.414 0.063 2.738 0.039 1.134 0.677 
BV-anaerobes RA endline 1.565 0.375 1.238 0.662 2.792 0.045 2.255 0.017 
 
Abbreviations: ART antiretroviral therapy, BV bacterial vaginosis, CIN cervical intraepithelial 
neoplasia, CT Chlamydia trachomatis, hrHPV high-risk human papillomavirus, NG Neisseria 
gonorrhoeae, RA relative abundance, aRRR adjusted relative risk ratio. Statistically significant 
results (p<0.05) are shown in bold.  
1.Each line represents one model. Each model includes the multi-category combined outcome and 
one independent variable. 
2.With ‘hrHPV’ we mean detection of any type. With ‘no hrHPV’ we mean that not a single high 
risk type was present.  
3.Comparing three categories: no, yes but not cohabiting, or cohabiting. The results are similar if 
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
analysed as an indicator variable. 
4.Comparing three categories: none, one, or two or more. The results are similar if analysed as an 
indicator variable. 
5.Comparing three categories: never, at one visit, and at both visits. The results are similar if 
analysed as an indicator variable. When four categories are analysed as an indicator variable 
(never, baseline only, endline only, or at both visits), hormonal contraceptive use at baseline and 
at both visits are both associated with CIN2+ compared to hrHPV twice, but hormonal 
contraceptive use at endline only is not. 
6.Comparing four categories: never, sometimes, always, or no sex in last six months. The results 
are similar if analysed as an indicator variable. 
7.Trichomonas vaginalis was only associated with hrHPV twice (RRR=2.544, p=0.142, compared 
to negative controls). Mycoplasma genitalium was not associated with any outcome. 
8.Not assessed at endline. 
9.Each line represents one multivariable model. All multivariable models included the multi-
category combined outcome, one VMB independent variable, age, CD4+ count at baseline or 
endline, and current hormonal contraceptive use (baseline) or any hormonal contraception during 
the study (endline). See Table S5 in Supplement 1, http://links.lww.com/QAD/B541 for 95% 
confidence intervals. 
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